{"cdcTestId":"2021-0034","testcaseName":"Patient is administered dose #1 at 11 years and dose #2 at 12 years with Pfizer Covid-19 vaccine (CVX 208)","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test Type","forecastTestType":"Recommended based on interval","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"2010-10-12T00:00:00","gender":"M"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-09-28T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2022-12-14T00:00:00","recommendedDate":"2022-12-14T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-09-28T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2021-08-22T20:00:00","dateUpdated":"2022-09-27T10:40:39.033","generalDescription":"This test case describes when a child is administered Pfizer Covid-19 vaccine (CVX 208) at age 11 and 12 years of age, that the doses are valid. A booster dose should be forecast.","changedInVersion":"4.27","reasonForChange":"v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group. \nv4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).\nv4.15 Updated the Forecast Dose Number field to blank."}